Effects of intravenous iron saccharate on improving severe anemia in rheumatoid arthritis patients |
| |
Authors: | Wei-Sheng Chen Chun-Yu Liu Hui-Ting Lee Kelvin Tsai Yi-Chun Lin Der-Cherng Tarng Chao-Hung Ho Hsiao-Yi Lin |
| |
Institution: | (1) Division of Allergy, Immunology and Rheumatology, Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China;(2) Division of Oncology and Hematology, Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China;(3) Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China;(4) National Yang Ming University School of Medicine, Taipei, Taiwan, Republic of China;(5) Division of Allergy, Immunology and Rheumatology, Wan-Fang Hospital, Taipei, Taiwan, Republic of China;(6) Institute of Clinical Medicine, National Yang Ming University, Taipei, Taiwan, Republic of China;(7) Institute of Biopharmaceutical Sciences, National Yang Ming University, Taipei, Taiwan, Republic of China;(8) Section of Allergy, Immunology and Rheumatology, Department of Medicine, Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei, 112, Taiwan, Republic of China; |
| |
Abstract: | Anemia in rheumatoid arthritis (RA) is multifactorial. Iron deficiency, either definite or relative (defect in iron utilization),
exists in RA patients with anemia. Intravenous iron therapy is indicated in severe and symptomatic cases or those with conditions
precluding use of oral iron, but its safety and long-term efficacy have not been well-established. Forty severe anemic (hemoglobin < 9 g/dL)
RA patients with or without demonstrable bone marrow iron stain were enrolled in this study. Fractionated administration of
intravenous iron saccharate was undertaken and the median follow-up time was 1 year. All patients exhibited significant elevations
of hemoglobin 3 months after treatment, which were more pronounced in the nonstainable iron marrow subjects {median (interquartile
range): 3.8 (2.9–4.8) g/dL versus 2.9 (2.0–3.0) g/dL, p < 0.01}. Thereafter, hemoglobin remained at a plateau level that lasted during the observation period. Throughout the whole
course, none of the cases exhibited side effects or flare up of disease activities. The use of intravenous iron saccharate,
preferably administrated in a fractionated way, is effective in the correction of severe anemia in RA patients, especially
those with nonstainable iron marrow. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|